Viatris Q3: Flat $3.75B Revenue, $325M Net Loss on $453M Tax Hit; Nashik Plant Suspended
VTRS sits 96% above its 52-week low of $9.92.
Summary
Viatris posted flat Q3 revenue of $3.75 billion but a $325.3 million net loss after a $453.2 million tax provision, and disclosed an FDA OAI classification at its Nashik plant with manufacturing suspended and about $100 million of Q4 revenue at risk.
Key Events · Earnings and Guidance · VTRS
-
Flat Revenue, Swing to Net Loss
Q3 2026 total revenues were $3,749.5 million versus $3,759.9 million a year earlier; net loss was $325.3 million, or $0.28 per diluted share, versus a $128.2 million loss in Q3 2025.
-
Tax Provision Jumps to $453M
The quarterly income tax provision rose to $453.2 million from $120.3 million, driven by losses in jurisdictions where minimal benefit can be realized; nine-month provision was $84.3 million.
-
Nashik Plant Hit With OAI Classification
The FDA classified the Nashik, India facility as Official Action Indicated in September 2026; Viatris voluntarily suspended manufacturing in October and expects to resume in Q1 2027, with roughly $100 million of Q4 2026 revenue impact and no expected 2027 recovery.
-
Buybacks Continue at $150M in Q3
Viatris repurchased 8.9 million shares for $150.0 million in Q3 and 18.3 million shares for $300.0 million over nine months, leaving $699.5 million available under the $2.0 billion program.
Analysis · VTRS · Life Sciences
Revenue was essentially flat at $3.75 billion, but the GAAP picture darkened: a $453.2 million quarterly tax provision (versus $120.3 million a year ago) pushed Viatris to a $325.3 million net loss, or $0.28 per share. The bigger operational issue is Nashik: the FDA classified the plant OAI in September, the company voluntarily halted manufacturing in October, and it now guides to roughly $100 million of lost revenue in Q4 2026 with no catch-up expected in 2027. That lands just as Viatris is asking Pacira holders to tender into its $36.50-a-share, $1.65 billion cash offer expiring November 16 — a deal it plans to fund mostly from excess cash. Cash generation remains the offset: $1.67 billion from operations over nine months and $1.79 billion of cash on hand.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VTRS was trading at $19.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.1B. The 52-week trading range was $9.92 to $19.51. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.